BioCryst Pharmaceuticals | 净收入



金融业
股票价格
USD
资产
USD 446.42M
现金及等价物
USD 84.08M
销售成本
USD 12.27M
流动资产
USD 355.68M
流动负债
USD 190.24M
债务
USD 828.6M
股息收益率
0
EBIT
USD -4.51M
EBITDA
USD -20.3M
员工
536
EPS每股收益
USD -0.13
股本和储备
USD -387.89M
销售毛利
USD -88.88M
债务利息支出
USD 24.45M
利息收入
USD -0.13
贷款资金
USD 194.37M
市值
USD 1.3B
净收入
USD -88.88M
营业费用
USD -387.89M
营业利润
USD -2.54M
普通股股本
USD 1.9M
PE价格收益
1.08K
税前利润
USD -86.95M
销售收入
USD -86.95M
销售和管理费用
USD 80.47M
股票
USD 5.23M
贸易债权人
USD 5.57M
应收帐款人
USD 79.07M


净收入 更改 日
Alnylam Pharmaceuticals USD 251.08M 317.36M 2025-09
BioCryst Pharmaceuticals USD -88.88M 74.85M 2024-12
Chugai Pharma JPY 128.41B 17.2B 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -33.16M 8.71M 2025-09
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 3.05B 1.09B 2025-09
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 2.71B 1.27B 2025-09
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -128.61M 252.16M 2025-09
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novavax USD -121.3M 283.68M 2024-09
PTC Therapeutics USD 15.9M 80.75M 2025-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -179.95M 376.84M 2025-09
Ultragenyx Pharmaceutical USD -180.41M 65.46M 2025-09
Vertex Pharmaceuticals USD 1.08B 50M 2025-09


BioCryst Pharmaceuticals 净收入 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.